An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...

Catheter ablation significantly reduces cardiovascular risks and mortality in patients with both atrial fibrillation and obstructive sleep apnea. The study involved over 18,000 patients, showing a ...

Expert discusses how emerging technologies like at-home testing and AI are redefining CKD screening and prevention for the ...

Expert discusses how health care teams must empower patients through ongoing dialogue, emphasizing shared decision-making and ...

A forward-looking analysis of how nonfactor therapies are transforming patient quality of life, clinician-patient collaboration, and the broader healthcare ecosystem for hemophilia management. The MHE ...

Expert discusses how chronic kidney disease ( CKD) and cardiovascular disease are interlinked, requiring proactive management ...

Sanofi is expanding options for those with hemophilia with its new treatment, Qfitlia (fitusiran). Approved this year, ...

Jeff Schaffnit discusses Sanofi's advancements in BTK inhibitors and promising results for hemophilia A therapies at ASH 2025 ...

The immunotherapies used to treat melanoma now include well-established drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) and newer ones such as Amtagvi (lifileucel), which uses T cells ...

Clinicians are moving toward managing mild (Grade 1) cytokine release syndrome on an outpatient basis. The most common and ...

The CAR T Vision Steering Committee members wish to double the number of eligible patients receiving chimeric antigen ...

Zevaskyn, the first gene therapy for recessive dystrophic epidermolysis bullosa, showed significant wound healing in phase 3 ...